PRITHVIRAJ BOSE to Primary Myelofibrosis
This is a "connection" page, showing publications PRITHVIRAJ BOSE has written about Primary Myelofibrosis.
Connection Strength
10.522
-
Moving beyond ruxolitinib failure in myelofibrosis: evolving strategies for second line therapy. Expert Opin Pharmacother. 2023 Jun; 24(9):1091-1100.
Score: 0.517
-
Cytopenic myelofibrosis: prevalence, relevance, and treatment. Expert Opin Pharmacother. 2023 Jun; 24(8):901-912.
Score: 0.513
-
Impact of SF3B1 mutation in myelofibrosis. Leuk Lymphoma. 2022 11; 63(11):2701-2705.
Score: 0.486
-
Disease Modification in Myelofibrosis: An Elusive Goal? J Clin Oncol. 2022 04 10; 40(11):1147-1154.
Score: 0.472
-
Novel strategies for challenging scenarios encountered in managing myelofibrosis. Leuk Lymphoma. 2022 04; 63(4):774-788.
Score: 0.465
-
SOHO State of the Art Updates and Next Questions: Identifying and Treating "Progression" in Myelofibrosis. Clin Lymphoma Myeloma Leuk. 2021 10; 21(10):641-649.
Score: 0.453
-
Management of myelofibrosis after ruxolitinib failure. Leuk Lymphoma. 2020 08; 61(8):1797-1809.
Score: 0.417
-
Mutational profiling in myelofibrosis: implications for management. Int J Hematol. 2020 Feb; 111(2):192-199.
Score: 0.403
-
New Concepts of Treatment for Patients with Myelofibrosis. Curr Treat Options Oncol. 2019 01 24; 20(1):5.
Score: 0.383
-
A phase 2 study of pracinostat combined with ruxolitinib in patients with myelofibrosis. Leuk Lymphoma. 2019 07; 60(7):1767-1774.
Score: 0.382
-
Novel treatment strategies for myeloproliferative neoplasms. Rinsho Ketsueki. 2019; 60(9):1176-1185.
Score: 0.381
-
Management of Myelofibrosis-Related Cytopenias. Curr Hematol Malig Rep. 2018 06; 13(3):164-172.
Score: 0.366
-
Janus kinase inhibition and symptom control in myeloproliferative neoplasms. Curr Med Res Opin. 2018 05; 34(5):935-937.
Score: 0.360
-
SOHO State-of-the-Art Update and Next Questions: MPN. Clin Lymphoma Myeloma Leuk. 2018 01; 18(1):1-12.
Score: 0.356
-
Developmental Therapeutics in Myeloproliferative Neoplasms. Clin Lymphoma Myeloma Leuk. 2017 07; 17S:S43-S52.
Score: 0.343
-
JAK2 inhibitors for myeloproliferative neoplasms: what is next? Blood. 2017 07 13; 130(2):115-125.
Score: 0.340
-
Investigational Janus kinase inhibitors in development for myelofibrosis. Expert Opin Investig Drugs. 2017 Jun; 26(6):723-734.
Score: 0.340
-
Drug Development Pipeline for Myeloproliferative Neoplasms: Potential Future Impact on Guidelines and Management. J Natl Compr Canc Netw. 2016 12; 14(12):1613-1624.
Score: 0.330
-
Myelofibrosis: an update on drug therapy in 2016. Expert Opin Pharmacother. 2016 Dec; 17(18):2375-2389.
Score: 0.328
-
Prognosis of Primary Myelofibrosis in the Genomic Era. Clin Lymphoma Myeloma Leuk. 2016 08; 16 Suppl:S105-13.
Score: 0.322
-
The evolution and clinical relevance of prognostic classification systems in myelofibrosis. Cancer. 2016 Mar 01; 122(5):681-92.
Score: 0.309
-
Moving toward disease modification in polycythemia vera. Blood. 2023 11 30; 142(22):1859-1870.
Score: 0.134
-
Pacritinib is a potent ACVR1 inhibitor with significant anemia benefit in patients with myelofibrosis. Blood Adv. 2023 10 10; 7(19):5835-5842.
Score: 0.133
-
Relevant Clinical Factors in Patients with Myelofibrosis on Ruxolitinib for 5 or More Years. Acta Haematol. 2023; 146(6):522-529.
Score: 0.132
-
The role of therapy in the outcome of patients with myelofibrosis. Cancer. 2023 09 15; 129(18):2828-2835.
Score: 0.129
-
Ten years after ruxolitinib approval for myelofibrosis: a review of clinical efficacy. Leuk Lymphoma. 2023 06; 64(6):1063-1081.
Score: 0.128
-
Myeloproliferative Neoplasms, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2022 09; 20(9):1033-1062.
Score: 0.123
-
Clinicopathologic spectrum of myeloid neoplasms with concurrent myeloproliferative neoplasm driver mutations and SRSF2 mutations. Mod Pathol. 2022 11; 35(11):1677-1683.
Score: 0.121
-
Improved survival of patients with myelofibrosis in the last decade: Single-center experience. Cancer. 2022 04 15; 128(8):1658-1665.
Score: 0.118
-
Momelotinib: an emerging treatment for myelofibrosis patients with anemia. J Hematol Oncol. 2022 01 19; 15(1):7.
Score: 0.118
-
SOHO State of the Art Updates and Next Questions: Novel Therapies in Development for Myelofibrosis. Clin Lymphoma Myeloma Leuk. 2022 04; 22(4):210-223.
Score: 0.116
-
Final results of a phase 2 clinical trial of LCL161, an oral SMAC mimetic for patients with myelofibrosis. Blood Adv. 2021 08 24; 5(16):3163-3173.
Score: 0.114
-
Mixed myeloid chimerism and relapse of myelofibrosis after allogeneic stem cell transplantation. Haematologica. 2021 07 01; 106(7):1988-1990.
Score: 0.113
-
Clinical Significance of Bone Marrow Blast Percentage in Patients With Myelofibrosis and the Effect of Ruxolitinib Therapy. Clin Lymphoma Myeloma Leuk. 2021 05; 21(5):318-327.e6.
Score: 0.110
-
Determining the recommended dose of pacritinib: results from the PAC203 dose-finding trial in advanced myelofibrosis. Blood Adv. 2020 11 24; 4(22):5825-5835.
Score: 0.109
-
Prognostic value of blasts in peripheral blood in myelofibrosis in the ruxolitinib era. Cancer. 2020 10 01; 126(19):4322-4331.
Score: 0.106
-
A phase 2 study of ruxolitinib in combination with azacitidine in patients with myelofibrosis. Blood. 2018 10 18; 132(16):1664-1674.
Score: 0.093
-
Clonal evolution and outcomes in myelofibrosis after ruxolitinib discontinuation. Blood. 2017 08 31; 130(9):1125-1131.
Score: 0.086
-
Patients with post-essential thrombocythemia and post-polycythemia vera differ from patients with primary myelofibrosis. Leuk Res. 2017 08; 59:110-116.
Score: 0.085
-
Haptoglobin is frequently low in patients with myelofibrosis: Clinical relevance. Leuk Res. 2017 06; 57:85-88.
Score: 0.084
-
Investigational histone deacetylase inhibitors (HDACi) in myeloproliferative neoplasms. Expert Opin Investig Drugs. 2016 Dec; 25(12):1393-1403.
Score: 0.082
-
Novel hematological parameters for the evaluation of patients with myeloproliferative neoplasms: the immature platelet and reticulocyte fractions. Ann Hematol. 2017 May; 96(5):733-738.
Score: 0.021